{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:24:48Z","timestamp":1777418688692,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report a case series of high-dose continuous infusion \u03b2-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>Continuous infusion ceftazidime or aztreonam was administered to achieve target drug concentrations at or above the minimum inhibitory concentration, when possible, in 3 patients with P. aeruginosa infections. The maximal calculated target drug concentration was 100 mg\/L. In the first patient, with primary immunodeficiency, neutropenia, and aggressive cutaneous T-cell lymphoma\/leukemia, continuous infusion ceftazidime (6.5-9.6 g\/day) was used to successfully treat multidrug-resistant P. aeruginosa bacteremia. In the second patient, with leukocyte adhesion deficiency type 1, continuous infusion aztreonam (8.4 g\/day) was used to successfully treat multidrug-resistant P. aeruginosa wound infections. In the third patient, with severe aplastic anemia, continuous infusion ceftazidime (7-16.8 g\/day) was used to treat P. aeruginosa pneumonia and bacteremia. In each patient, bacteremia cleared, infected wounds healed, and pneumonia improved in response to continuous infusion ceftazidime or aztreonam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Treatment strategies for multidrug-resistant P. aeruginosa infections are limited. A novel treatment strategy, when no other options are available, is the continuous infusion of existing \u03b2-lactam antibiotics to maximize their pharmacodynamic activity. High-dose continuous infusion ceftazidime or aztreonam was used for the successful treatment of resistant systemic P. aeruginosa infections in 3 chronically immunocompromised patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Continuous infusion \u03b2-lactam antibiotics are a potentially useful treatment strategy for resistant P.aeruginosa infections in immunocompromised patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1m717","type":"journal-article","created":{"date-parts":[[2010,4,7]],"date-time":"2010-04-07T01:43:42Z","timestamp":1270604622000},"page":"929-935","source":"Crossref","is-referenced-by-count":42,"title":["High-Dose Continuous Infusion \u03b2-Lactam Antibiotics for the Treatment of Resistant\n                    <i>Pseudomonas Aeruginosa<\/i>\n                    Infections in Immunocompromised Patients"],"prefix":"10.1177","volume":"44","author":[{"given":"Brad","family":"Moriyama","sequence":"first","affiliation":[{"name":"Brad Moriyama PharmD, Clinical Pharmacist, National Institutes of Health Clinical Center Pharmacy Department, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey A","family":"Henning","sequence":"additional","affiliation":[{"name":"Stacey A Henning PharmD, Clinical Pharmacist, National Institutes of Health Clinical Center Pharmacy Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Childs","sequence":"additional","affiliation":[{"name":"Richard Childs MD, Senior Investigator, National Heart, Lung, and Blood Institute, Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M","family":"Holland","sequence":"additional","affiliation":[{"name":"Steven M Holland MD, Senior Investigator, National Institute of Allergy and Infectious Diseases, Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria L","family":"Anderson","sequence":"additional","affiliation":[{"name":"Victoria L Anderson RN, National Institute of Allergy and Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C","family":"Morris","sequence":"additional","affiliation":[{"name":"John C Morris MD, Senior Investigator, National Cancer Institute, Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wyndham H","family":"Wilson","sequence":"additional","affiliation":[{"name":"Wyndham H Wilson MD, Senior Investigator, National Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L","family":"Drusano","sequence":"additional","affiliation":[{"name":"George L Drusano MD, Senior Scientist, Ordway Research Institute, Albany, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J","family":"Walsh","sequence":"additional","affiliation":[{"name":"Thomas J Walsh MD FACP FAAM FIDSA, Senior Investigator, Chief, Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,5,1]]},"reference":[{"key":"bibr1-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-6553(99)70031-3"},{"key":"bibr2-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.12.019"},{"key":"bibr3-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1306-1311.2005"},{"key":"bibr4-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705653"},{"key":"bibr5-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1378\/chest.109.4.1019"},{"key":"bibr6-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1086\/499819"},{"key":"bibr7-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.3.297"},{"key":"bibr8-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2008.02.003"},{"key":"bibr9-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.9.1320"},{"key":"bibr10-aph.1M717","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666010-00001"},{"key":"bibr11-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"bibr12-aph.1M717","unstructured":"Bauer LA Applied clinical pharmacokinetics. New York: McGraw-Hill, 2001:39\u201341."},{"key":"bibr13-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.1.5"},{"key":"bibr14-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L638"},{"key":"bibr15-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"bibr16-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91741-2"},{"key":"bibr17-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.125"},{"key":"bibr18-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.8.620.31525"},{"key":"bibr19-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1007\/PL00008370"},{"key":"bibr20-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90561-8"},{"key":"bibr21-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00174-09"},{"key":"bibr22-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200103270-00009"},{"key":"bibr23-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20791"},{"key":"bibr24-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1086\/339215"},{"key":"bibr25-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.931"},{"key":"bibr26-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1159\/000007198"},{"key":"bibr27-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.5.617"},{"key":"bibr28-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh381"},{"key":"bibr29-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg467"},{"key":"bibr30-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh536"},{"key":"bibr31-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-005-0021-y"},{"key":"bibr32-aph.1M717","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.4.405"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M717","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1M717","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:36Z","timestamp":1777374456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1M717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1345\/aph.1M717"],"URL":"https:\/\/doi.org\/10.1345\/aph.1m717","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}